Juvena Therapeutics
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
640 Galveston Dr, Redwood City, Californ...Phone Number
(650) 223-5879Website
www.juvenatherapeutics.comRevenue
$11.4 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
2
1
1
1
1
1
About Juvena Therapeutics
Juvena Therapeutics is a clinical-stage biotechnology company developing regenerative biologics designed to restore tissue function by translating insights from human biology into engineered therapeutics. The company is advancing a pipeline of programs targeting neuromuscular and age-related diseases, with the goal of delivering disease-modifying treatments for serious unmet medical needs.Explore more
Juvena Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Juvena Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Juvena Therapeutics launches new products
Earning: See what the market has to say on Juvena Therapeutics recently announced quarterly report
Check out if Juvena Therapeutics is spiking on competitors!
Click to see if Juvena Therapeutics had a recent Job posting/layoffs
Juvena Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Juvena Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Juvena Therapeutics
Check if Juvena Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Juvena Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Juvena Therapeutics
Compare insights from companies similar to Juvena Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Juvena Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Juvena Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Juvena Therapeutics.
Juvena Therapeutics financials insights
Gather financial insights about Juvena Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$41M
2025
Stock/Share Issuance
$30.5M
2026
Series B
$33.5M
Juvena Therapeutics Tech Stack
A closer look at the technologies used by Juvena Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Open Position
Open Position
Juvena Therapeutics News & Media
Juvena Therapeutics and Lilly Enter Research Collaboration Focused on Muscle Health
Lilly taps Juvena's AI platform, the first to map the therapeutic potential of secreted proteins, to discover treatments that improve muscle health.Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161
REDWOOD CITY, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, announced today that it is enrolling participants into its clinical trial evaluating JUV-161, a first-in-class fusion protein that enhances muscle regeneration through its pro-myogenic, insulin-resistance modulating, and anti-inflammatory properties. JUV-161 is a muscle regenerating eJuvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Juvena Therapeutics, a biotechnology company unlocking the potential of stem cell-secreted proteins to treat muscle and metabolic diseases including muscular dystrophies and obesity, today announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to the company’s flagship candidate, JUV-161. JUV-161 is an investigational therapeutic for the treatment of Myotonic Dystrophy Type 1 (DM1), a rare, multi-systemic, autosomal dominantNIA-Funded Small Business Spotlight: Juvena Therapeutics Unlocking the Secrets of Tissue ...
NIA funding is enabling innovation at Juvena, a small business working to unlock the secrets of proteins for regenerative medicine.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Juvena Therapeutics
Sign Up For FreeTo access detailed company insights
Juvena Therapeutics is a clinical-stage biotechnology company developing regenerative biologics designed to restore tissue function by translating insights from human biology into engineered therapeutics. The company is advancing a pipeline of programs targeting neuromuscular and age-related diseases, with the goal of delivering disease-modifying t... Read More
